

Development of a SPE LC-MS/MS Method Utilizing QuanRecovery Sample Plates with MaxPeak High Performance Surfaces for the Bioanalytical Quantification of Pramlintide from Serum

Caitlin Dunning, Mary Lane, Mark Wrona, and Kim Haynes
 Waters Corporation, Milford, MA, USA

APPLICATION BENEFITS

- Waters™ Oasis™ Peptide Separation Technologies (PST) μ Elution™ SPE screening protocol facilitates fast SPE method development for peptides
- QuanRecovery™ LC-MS compatible sample plates with MaxPeak™ High Performance Surfaces mitigated non-specific binding of pramlintide and enabled desired limits of detection to be achieved
- ACQUITY™ UPLC™ Peptide CSH Columns for improved selectivity, high sensitivity, and narrow peak widths
- High sensitivity and accuracy achieved using UPLC separation and Xevo™ TQ-XS Mass Spectrometer

WATERS SOLUTIONS

[Oasis WCX \$\mu\$ Elution SPE Plate](#)

[QuanRecovery Plates](#)

[ACQUITY UPLC Peptide CSH Columns](#)

[ACQUITY UPLC I-Class PLUS System](#)

[Xevo TQ-XS Tandem Quadrupole Mass Spectrometer](#)

[MassLynx™ v4.2 Software](#)

[TargetLynx™ Application Manager](#)

KEYWORDS

Pramlintide, SYMLIN, peptide quantification, serum, bioanalysis, QuanRecovery with MaxPeak High Performance Surfaces, solid phase extraction, μ Elution SPE, Oasis WCX, SPE, UPLC, ACQUITY Peptide CSH, ACQUITY UPLC I-Class PLUS, Xevo TQ-XS, non-specific binding

INTRODUCTION

Pramlintide acetate (SYMLIN™) is a 37 amino acid (MW 3949.4 Da) synthetic analogue of the human hormone amylin (Figure 1). Developed as an adjunctive therapy for patients with Type 1 and 2 diabetes, this peptide can improve treatment outcomes for those who have failed to achieve glycemic control despite optimal insulin therapy.¹ With nearing patent expiry dates for pramlintide,² and recent research indicating a role for amylin in Alzheimer's Disease models,³ interest in amylin and amylin agonists is rising. Characterized by fast absorption (<30 minutes), elimination (~1 hour), and low circulating levels (pg/mL), amylin agonists such as pramlintide can be challenging to quantify. LC-MS/MS assays have become increasingly popular for peptide quantification due to the high sensitivity and specificity afforded by selective MRM fragments. However, method development and accurate quantification for hydrophobic peptides like pramlintide can still be challenging because peptides notoriously suffer from non-specific binding (adsorption). This can lead to poor recovery, loss of analyte, and poor limits of detection. The work described here uses a selective sample preparation strategy and LC-MS compatible sample storage plates with high performance surfaces to mitigate pramlintide loss due to non-specific binding. In addition to this, we will show that optimized UPLC separation and column chemistry, along with a highly sensitive tandem quadrupole mass spectrometry method can produce significantly lower limits of quantification. For this assay, an LLOQ of 25 pg/mL of pramlintide was achieved, extracted from 100 μ L of rat and human serum.




Figure 1. Pramlintide amino acid sequence and molecular weight.

EXPERIMENTAL

Sample preparation

Preparation of samples, calibration standards, and QC samples

Calibration curve standards and quality control (QC) samples of pramlintide (ProSpec Bio, Rehovot, Israel, p/n: HOR-300) were prepared in commercially available human and rat serum at various concentration levels (25–50,000 pg/mL). All calibration curve standards, QC levels, and blank (non-spiked) samples were prepared in triplicate.

SPE using Oasis WCX 96-well μ Elution Plate

One hundred microliters of serum was diluted with 100 μ L of water and vortexed. All wells of an Oasis WCX 96-well μ Elution Plate (p/n: [186002499](#)) were conditioned with 200 μ L of methanol and then equilibrated with 200 μ L of water. The diluted serum samples (200 μ L) were loaded onto the SPE plate, subsequently washed with 200 μ L of water, and followed by 200 μ L of 20% acetonitrile in water. Pramlintide was eluted from the sorbent using a 1 \times 25 μ L aliquot of the elution solvent containing 1% trifluoroacetic acid in 75:25 (v/v) acetonitrile:water. Eluates were collected in a QuanRecovery LC-MS compatible sample plate with MaxPeak High Performance Surfaces (p/n: [186009184](#)), and then diluted with 25 μ L of water for a final sample volume of 50 μ L. Ten microliters of each sample were injected onto an ACQUITY UPLC I-Class PLUS System equipped with an ACQUITY UPLC Peptide CSH C₁₈, 2.1 \times 50 mm Column (p/n: [186006936](#)) and a Xevo TQ-XS Mass Spectrometer.

Method conditions

LC system:	ACQUITY UPLC I-Class PLUS (fixed loop)	Cone gas flow:	150 L/hr
Detection:	Xevo TQ-XS Mass Spectrometer, ESI+	Desolvation gas flow:	1000 L/hr
Column:	ACQUITY UPLC Peptide CSH C ₁₈ , 130 Å, 1.7 μ m, 2.1 \times 50 mm (p/n: 186006936)	Collision gas flow:	0.15 mL/min
Column temp.:	60 °C	Nebulizer gas flow:	7 bar
Sample temp.:	15 °C	System calibration:	Low resolution
Injection volume:	10 μ L	Data management:	MassLynx (v4.2)
Mobile phase A:	0.1% Formic acid in water	Quantification software:	TargetLynx XS
Mobile phase B:	0.1% Formic acid in acetonitrile	LC gradient:	
MS system:	Xevo TQ-XS		
Ionization mode:	ESI+	<u>Time</u>	<u>Flow rate</u>
Capillary:	1.0 kV	(min)	(mL/min)
Cone:	15 V	Initial	0.400
Source offset:	30 V	0.50	0.400
Source temp.:	150 °C	1.00	0.400
Desolvation temp.:	600 °C	4.00	0.400
		4.75	0.400
		5.50	0.400
		6.00	0.400
		7.00	0.400
		<u>%A</u>	<u>%B</u>
		80.0	20.0
		80.0	20.0
		78.0	22.0
		73.0	27.0
		5.0	95.0
		5.0	95.0
		80.0	20.0
		80.0	20.0
		<u>Curve</u>	
		6	
		6	
		6	
		6	
		6	
		6	
		6	

Table 1. Mass spectrometry conditions for pramlintide, including precursor and fragment ions.

Precursor (m/z)	Product (m/z)	Cone voltage (V)	Collision energy (eV)	Product ion identification	
988.36	968.11	15	20	[3H+]3/b27	Primary
988.36	930.78	15	26	[4H+]4/y35	Confirmatory

RESULTS AND DISCUSSION

SAMPLE HANDLING: QUANRECOVERY WITH MAXPEAK HIGH PERFORMANCE SURFACES

Larger and more hydrophobic molecules, including peptides, often suffer from non-specific binding (NSB) or adsorption to any labware that samples come in contact with (e.g., plates, vials, pipette tips).⁴ A commonly used strategy to mitigate the effects of non-specific binding of the molecules of interest is to add carrier protein(s) to the sample. This can be done prior to sample cleanup and/or immediately prior to LC-MS/MS analysis of the analyte. Although generally highly effective, adding carrier proteins to a sample also adds more complexity to the sample, which sample preparation seeks to eliminate. In recent years, scientists have found more innovative ways to mitigate non-specific binding. Waters developed QuanRecovery LC-MS sample plates and vials with MaxPeak High Performance Surfaces which mitigate, and in some cases eliminate, non-specific binding of peptides to the surface of the container.

Pramlintide is a large peptide (MW 3949.4 Da) which is hydrophobic (HPLC Index: 88.7) and can therefore be expected to suffer from some degree of non-specific binding. During method development, pramlintide was stored in either a QuanRecovery sample plate or a standard polypropylene plate prior to LC-MS/MS analysis in order to assess the plates' effectiveness in mitigating NSB. Test samples were prepared and stored in neat solution, while additional samples prepared in a solution containing carrier proteins were used as a benchmark for 100% recovery. Results from this assessment showed that pramlintide suffered from a high degree of NSB to a standard polypropylene plate, while the QuanRecovery Plate was able to significantly mitigate the effects of NSB as seen in Figure 2. Recovery of 10 ng/mL pramlintide from the QuanRecovery Plate was almost 100%, leading to a peak area ~36 times higher than samples stored in a standard polypropylene plate where analyte recovery was only ~3%. Although this strategy combats pre-analytical NSB of our peptide of interest, it is important to keep in mind that peptides can adsorb to any surface they come in contact with prior to entering the mass spectrometer (including any plate transfer steps or system loss). For all analytes, it is important to determine if pre-analytical mitigation of non-specific binding is enough to reach the desired limits of detection of your assay. In some cases, it may still be necessary to use both carrier protein addition and high-performance surface sample storage containers to ensure that your analyte is not lost due to adsorption. Pramlintide benefits from the use of QuanRecovery Plates and Vials post SPE extraction to reach the desired limits of detection of this assay.




Figure 2. Peak area and recovery of 10 ng/mL pramlintide stored in standard polypropylene and QuanRecovery 96-well Plates with MaxPeak High Performance Surfaces.

SAMPLE PREPARATION: SPE METHOD DEVELOPMENT

Solid-phase extraction (SPE) is a simple, robust, and fast sample preparation method which can be used to extract analytes from complex matrices. The Oasis Peptide Separation Technology (PST) μ Elution SPE screening strategy (Figure 3, Panel A), specifically designed for peptides, provides the user with simple methods to quickly screen multiple SPE sorbents (Oasis MAX and WCX) to assess recovery and matrix effects of the peptide of interest. Using this strategy, pramlintide was screened and it resulted in starting recoveries of ~46 and 58%, respectively. The calculated isoelectric point (pI) of pramlintide is 10.2 indicating that this peptide will be positively charged under most SPE conditions. Due to this, and the higher recovery achieved in the initial screening experiment, the **Weak Cation-eXchange** sorbent, Oasis WCX, was best suited for the extraction of pramlintide.

Through additional optimization experiments, it was determined that pramlintide was not adequately retained on the WCX sorbent during sample loading and Wash 1 with 5% NH_4OH (pH ~12). Pramlintide is a basic peptide, as indicated by its pI, and is largely negatively charged at this pH, leading to poor retention on the negatively charged SPE sorbent. Changing the pretreatment solution and Wash 1 solvent to water (pH <7) ensured that the sorbent remained negatively charged, and pramlintide remained positively charged during both loading and Wash 1. Wash 2 and the elution solution used in the PST protocol remain the same in the optimized protocol, as it was determined during method optimization that trifluoroacetic acid was effective at fully eluting pramlintide from the SPE sorbent. Weaker acids such as formic acid and acetic acid were assessed and resulted in very low recoveries of the analyte (<10%). With the combination of this optimized protocol and chromatography gradient (discussed below), recovery of pramlintide was improved to ~75% (Figure 3, Panel B).




Figure 3. SPE protocols and results. Oasis PST SPE protocol for peptides (A), and optimized Oasis WCX SPE protocol for the extraction of pramlintide from serum (B).

CHROMATOGRAPHY

Optimization of chromatography was essential to the success of this assay. During method development of pramlintide, several reversed-phase columns were assessed for overall chromatographic performance (not shown). It was determined that the ACQUITY UPLC Peptide CSH C_{18} Column, with its positively charged surface, provided the best selectivity and sensitivity, with a 5-fold improvement in signal to noise compared to the ACQUITY UPLC Peptide BEH C_{18} Column.

Despite the improved selectivity and sensitivity afforded by the ACQUITY UPLC Peptide CSH C_{18} Column, matrix interferences from extracted serum samples were still high, leading to signal suppression. During method development, a screening gradient from 15–60% mobile phase B (MPB) over two minutes was used. Initial results determined there was significant signal suppression (~20%) as compared to a non-extracted pramlintide sample. Modifying the gradient and increasing the starting percentage of organic solvent MPB from 15–20% significantly decreased the matrix background entering the mass spectrometer. In order to properly separate pramlintide from remaining matrix interferences at very low concentrations, the gradient was shallowed to 22–27% MPB over three minutes.

The combination of selective column chemistry and a highly optimized gradient resulted in reduction of observed matrix suppression (<10%) and improved pramlintide peak area, greatly improving both selectivity and sensitivity (Figure 4).




Figure 4. Screening vs. optimized gradient. Representative chromatograms of 100 pg/mL pramlintide extracted from rat serum and separated using a screening chromatography gradient and an optimized gradient. The optimized gradient significantly improved matrix suppression from ~20% to less than 10%, and decreased the chromatographic baseline to acceptable levels.

MASS SPECTROMETRY

LC-MS/MS quantification of pramlintide was performed using a Xevo TQ-XS Mass Spectrometer and low resolution calibration (1.0 Da at FWHM) to achieve better assay sensitivity. When working with a lower resolution system calibration, it is critically important to use selective MRM fragments with high m/z values for quantification in order to avoid high background and matrix interferences. During method development, three predominant precursors were observed at 1317.48 (3+), 988.36 (4+), and 790.89 (5+) m/z , with the 4+ precursor resulting in the most intense fragments. Via manual tuning, an intense fragment of the 4+ precursor was identified at 968.11 m/z , corresponding to the b-ion cleavage between Leu-27 and Pro-28. This highly selective and intense fragment of pramlintide was used as the primary quantification transition, while the y-ion transition at 930.78 m/z was used as a qualifier. Optimized MS conditions and MRM transitions used for quantification of pramlintide are listed in Table 1.

LINEARITY, PRECISION, AND ACCURACY

Linear, precise, and accurate quantification of pramlintide was achieved using only 100 μ L of human or rat serum. Limits of detection (LOD) of 10 pg/mL and lower limits of quantification (LLOQs) of 25 pg/mL were achieved for both human and rat serum. Calibration curves were linear ($r^2 > 0.99$) from 25–50,000 pg/mL using a $1/X^2$ linear fit (Table 2). All calibration curves and QC levels were accurate within $\pm 15\%$ and CVs were $< 5\%$. QC performance is highlighted in Table 3 where all statistics met recommended bioanalytical method validation guidelines, and chromatographic performance is illustrated in Figure 5.

Table 2. Linear dynamic range and standard curve statistics for pramlintide extracted from human and rat serum.

Species	Curve (pg/mL)	Weighting	Linear fit (r^2)	% Accuracy range
Human	25–50,000	$1/X^2$	0.995	91.3–111.0
Rat	25–50,000		0.996	92.3–105.9

Table 3. QC quantitative performance for pramlintide extracted from human serum (A) and rat serum (B).

A Human serum QC statistics				
QC level	QC concentration (pg/mL)	Mean (N=3) calculated QC concentration (pg/mL)	Mean (N=3) % accuracy	Mean (N=3) % CV
LLOQ	25	24.0	96.1	3.5
LQC	75	77.4	103.3	5.0
MQC	2500	2619.1	104.8	1.1
HQC	40000	39309.7	98.3	2.8

B Rat serum QC statistics				
QC level	QC concentration (pg/mL)	Mean (N=3) calculated QC concentration (pg/mL)	Mean (N=3) % accuracy	Mean (N=3) % CV
LLOQ	25	23.5	93.9	3.7
LQC	75	72.2	96.2	3.1
MQC	2500	2512.6	100.5	5.2
HQC	40000	36628.5	91.6	1.7




Figure 5. Representative blank, LLOQ, and LQC chromatograms for pramlintide extracted using Oasis WCX μ Elution SPE from 100 μ L of human and rat serum.

CONCLUSIONS

The work described here employs a simple sample preparation strategy using Oasis WCX μ Elution SPE and QuanRecovery Sample Plates with MaxPeak High Performance Surfaces. Combining this approach with UPLC separation and a tandem quadrupole MS resulted in high sensitivity quantification of pramlintide from human and rat serum.

- Sample preparation with simple SPE allowed for fast extraction (<2 hours) of pramlintide from complex matrices
- QuanRecovery Sample Plates effectively mitigated non-specific binding and provided a 36-fold increase in pramlintide peak area in neat solution
- Use of a sub-2- μ m ACQUITY UPLC Peptide CSH C₁₈ Column and optimized chromatography gradients provided improved analyte selectivity and a significant decrease in matrix suppression of the assay
- Using only 100 μ L of human (or rat) serum, a LLOQ of 25 pg/mL was achieved with excellent precision (CVs <5%) and accuracy

References

1. Center for Drug Evaluation and Research Approval Package for Application Number 21-332. Clinical Pharmacology and Biopharmaceutics Review. Retrieved 09Jan2019 from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/21-332_Symlin%20Injection_biopharmr.PDF.
2. SYMLIN Product Information, Retrieved 09Jan2019 from <https://www.drugs.com/availability/generic-symlin.html>.
3. Mohamed, L.A.; Zhu, H.; Mousa, Y.M.; Wang, E.; Qiu, W.Q.; Kaddoumi, A. Amylin Enhances Amyloid- β Peptide Brain to Blood Efflux Across the Blood-Brain Barrier. *J. Alzheimers Dis.* **2017**, *56* (3), 1087-1099.
4. Rabe, M.; Verdes, D.; Seeger, S. Understanding Protein Adsorption Phenomena at Solid Surfaces. *Adv. Colloid Interface Sci.* **2011**, *162* (1-2), 87-106.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Waters, The Science of What's Possible, QuanRecovery, MaxPeak, ACQUITY, UPLC, Xevo, Oasis, μ Elution, MassLynx, and TargetLynx are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2019 Waters Corporation. Produced in the U.S.A. March 2019 720006527EN AG-PDF

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com